Fatigue News and Research

RSS

Mylan gets tentative approval from FDA for two pediatric dosages of abacavir/lamivudine tablets

Mylan Inc. today announced that its subsidiary Mylan Laboratories Limited has received tentative approval from the U.S. Food and Drug Administration for its New Drug Applications (NDAs) for two dosages of abacavir/lamivudine tablets for oral suspension for the treatment of HIV-1 infection in pediatric patients.

4 Dec 2014

Massage therapy: A natural way to strengthen the immune system this flu season

As seasons change our bodies become more susceptible to cold and flu. Massage therapy is a natural way to strengthen the immune system at this vulnerable time, especially if it is already weakened by stress, fatigue or poor nutrition.

4 Dec 2014

Pharmacyclics wins 2014 Society for Medicines Research Award for Drug Discovery

Pharmacyclics, Inc. today announced that it has won the prestigious 2014 Society for Medicines Research Award for Drug Discovery for its discovery of ibrutinib (IMBRUVICA). The award was presented by The Society of Medicines Research at its biennial award lecture in Kensington, London.

4 Dec 2014

BeyondSpring Pharmaceuticals plans to initiate Plinabulin Phase 3 pivotal trial in NSCLC patients

BeyondSpring Pharmaceuticals, Inc., a clinical stage biopharmaceutical company focused on the development of innovative cancer therapies, today announced that it plans to initiate a Phase 3 pivotal trial of lead product candidate, Plinabulin, in patients with non-small cell lung cancer (NSCLC) in the first quarter of 2015.

4 Dec 2014

Study: Common prostate cancer therapy exposes low-risk patients to more adverse side effects

A common prostate cancer therapy should not be used in men whose cancer has not spread beyond the prostate, according to a new study led by researchers at Henry Ford Hospital.

4 Dec 2014

Prodromal symptoms precede PD by up to a decade

Many prodromal symptoms of Parkinson’s disease appear long before a clinical diagnosis is made, shows a large study of patients in primary care.

3 Dec 2014

EMA accepts new IMBRUVICA (ibrutinib) application for treatment of Waldenstrom's macroglobulinemia

Pharmacyclics, Inc.today announced the acceptance of a Type II variation application for IMBRUVICA (ibrutinib) by the European Medicines Agency.

1 Dec 2014

New eye test objectively measures level of fatigue that doctors may feel after long shifts

An international team of scientists which includes researchers from the U. of Granada has demonstrated for the first time that it is possible to establish in an objective way the level of fatigue in physicians after long shifts through their eye movement.

28 Nov 2014

UT Arlington researcher receives grant to educate Hispanic patients about depression, treatment options

A University of Texas at Arlington researcher hopes to dispel myths about depression and its treatment, as well as reduce the stigma associated with receiving mental health care among Hispanics.

27 Nov 2014

Scientists make breakthrough in developing new treatment for advanced bladder cancer

Scientists from Queen Mary University of London have made a breakthrough in developing a new therapy for advanced bladder cancer - for which there have been no major treatment advances in the past 30 years.

26 Nov 2014

Long-term T therapy in hypogonadal men is safe, does not increase PCa risk, study finds

Testosterone (T) therapy is routinely used in men with hypogonadism, a condition in which diminished function of the gonads occurs. Although there is no evidence that T therapy increases the risk of prostate cancer (PCa), there are still concerns and a paucity of long-term data.

25 Nov 2014

Children with NAFLD at substantial risk for high blood pressure

High blood pressure and nonalcoholic fatty liver disease (NAFLD) are two emerging health problems related to the epidemic of childhood obesity. In a recent study, researchers at University of California, San Diego School of Medicine sought to determine the prevalence of high blood pressure in children with NAFLD, which places them at risk for premature cardiovascular disease.

24 Nov 2014

Accelerated treatment regimen feasible for advanced NSCLC

A treatment strategy designed to minimise the effects of accelerated repopulation using hypofractionated radiotherapy with chemotherapy is feasible for patients with stage III non-small-cell lung cancer, according to UK researchers.

21 Nov 2014

UH professor receives NIH grant for breast cancer research

After earning her medical degree in China, Qian Lu, an associate professor of psychology at the University of Houston, felt she could help patients more by treating the mind as well as the body. She then decided to pursue a doctorate in psychology in the U.S.

21 Nov 2014

A new method for determining onset of elevated influenza activity at community level

Predicting the beginning of influenza outbreaks is notoriously difficult, and can affect prevention and control efforts.

20 Nov 2014

New oral medication shows promise in treating fibromyalgia

A new oral medication known as IMC-1, developed by Innovative Med Concepts, proved highly effective at reducing pain and other symptoms of fibromyalgia (FM) in patients in a recent clinical trial.

18 Nov 2014

Vital exhaustion may increase risk of first-time cardiovascular disease by 36%

Fatigue, increased irritability, and feeling demoralized, may raise a healthy man or woman's risk of first-time cardiovascular disease by 36 percent, according to a study led by researchers at Mount Sinai St. Luke's and Mount Sinai Roosevelt hospitals presented on Nov. 17 at the American Heart Association's Scientific Sessions 2014 in Chicago, IL.

17 Nov 2014

Two hospital staff shortlisted as finalists in NHS Leadership Recognition Awards

A CONSULTANT nurse leading the way in cancer care and a manager inspiring a generation of NHS professionals to improve the quality, safety and value of care they provide are to be recognised at a regional award scheme celebrating great leaders in the NHS.

17 Nov 2014

Sanofi, Genzyme announce FDA approval of Lemtrada for treatment of relapsing forms of MS

Sanofi and its subsidiary Genzyme announced today that the U.S. Food and Drug Administration has approved Lemtrada (alemtuzumab) for the treatment of patients with relapsing forms of multiple sclerosis (MS). Because of its safety profile, the use of Lemtrada should generally be reserved for patients who have had an inadequate response to two or more drugs indicated for the treatment of MS.

17 Nov 2014

New wearable technology could send personalized health alerts to troops, civilians

Wearable devices can count the steps you take and the calories you burn. But can they help soldiers in the field? Or prevent someone from having a heart attack?

13 Nov 2014

Fatigue News and Research

Mylan gets tentative approval from FDA for two pediatric dosages of abacavir/lamivudine tablets

Massage therapy: A natural way to strengthen the immune system this flu season

Pharmacyclics wins 2014 Society for Medicines Research Award for Drug Discovery

BeyondSpring Pharmaceuticals plans to initiate Plinabulin Phase 3 pivotal trial in NSCLC patients

Study: Common prostate cancer therapy exposes low-risk patients to more adverse side effects

Prodromal symptoms precede PD by up to a decade

EMA accepts new IMBRUVICA (ibrutinib) application for treatment of Waldenstrom's macroglobulinemia

New eye test objectively measures level of fatigue that doctors may feel after long shifts

UT Arlington researcher receives grant to educate Hispanic patients about depression, treatment options

Scientists make breakthrough in developing new treatment for advanced bladder cancer

Long-term T therapy in hypogonadal men is safe, does not increase PCa risk, study finds

Children with NAFLD at substantial risk for high blood pressure

Accelerated treatment regimen feasible for advanced NSCLC

UH professor receives NIH grant for breast cancer research

A new method for determining onset of elevated influenza activity at community level

New oral medication shows promise in treating fibromyalgia

Vital exhaustion may increase risk of first-time cardiovascular disease by 36%

Two hospital staff shortlisted as finalists in NHS Leadership Recognition Awards

Sanofi, Genzyme announce FDA approval of Lemtrada for treatment of relapsing forms of MS

New wearable technology could send personalized health alerts to troops, civilians

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest News